Jake Legal Medical Disclaimer The information provided on this siteincluding articles, newsletters, social-media posts, videos, and downloadable resourcesis intended for general educational purposes only and does not constitute medical advice, diagnosis, or treatment
10.1016/s1050-1738(99)00020-21 Trends Cardiovasc Med
DSIP remains a research compound in Canada and is not approved for therapeutic use, but its favorable safety profile and unique mechanism have made it increasingly popular among biohackers, athletes, and those struggling with sleep disturbances
**Free Nutrition + Mental Health Guidance** Exclusive NAD+ Loyalty Pricing - lowest you'll find
2 Treatment groups Experimental Treatment Placebo Group Participants will receive 0.25 mg once weekly semaglutide injection for 4 weeks